SynthesisBMC ophthalmology2026
Comparison of the clinical effect of intravitreal ranibizumab and intravitreal dexamethasone implants in the treatment of retinal vein occlusion complicated with macular oedema: a meta-analysis.
Synthesis in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate and compare the clinical efficacy of intravitreal ranibizumab (RNZ) and intravitreal dexamethasone (DEX) implants in the treatment of retinal vein occlusion (RVO) complicated with macular oedema (MO).
methodsFive English-language databases were searched from database establishment to August 2025. In this study, the RevMan 5.3 statistical software package was used.
resultsA total of 10 articles involving 1,274 patients were included. A meta-analysis showed that intravitreal RNZ was superior to intravitreal DEX implants in improving visual acuity in patients with RVO complicated by MO. In patients with central RVO (CRVO), best-corrected visual acuity (BCVA) improved more significantly in the RNZ-treated group than in the DEX group at 6 months (p < 0.001). For patients with branch RVO (BRVO), the RNZ group showed better BCVA improvement than the DEX group at both 1 and 3 months (p < 0.001). Best-corrected visual acuity had improved more at 1 month in the RNZ group (p < 0.001) than in the DEX group. Ranibizumab was superior to DEX in reducing central retinal thickness (CRT) at 3 months in patients with BRVO and in those with CRVO. Patients with BRVO showed a significant decline in CRT at 3 months (p < 0.001) and 6 months (p = 0.005), and patients with CRVO also had a significant improvement in CRT at 6 months (p = 0.005). However, intraocular pressure was higher in the intravitreal DEX group than in the RNZ group (p < 0.001).
conclusionIntravitreal RNZ is superior to intravitreal DEX implants in improving BCVA and reducing CRT in patients with RVO complicated with MO; however, RNZ is injected more frequently. These findings are primarily derived from short-to-medium-term evidence, highlighting a need for longer-term comparative data. Furthermore, it should be noted that most included studies did not stratify outcomes by ischaemic status, which is a relevant clinical consideration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.